Kraig Biocraft Laboratories Inc

Kraig Biocraft Laboratories Inc has a negative equity position of -$7.999 million and a debt-to-equity ratio of -0.19, indicating a capital structure heavily reliant on debt and negative equity. The company's liquidity is constrained, with a current ratio of 0.18, suggesting limited ability to meet short-term obligations. Free cash flow is negative at -$3.604 million, and operating cash flow is -$1.789 million, reflecting ongoing cash outflows from operations. Profitability metrics are weak, with a return on equity of 0.453 and a return on assets of -1.4123. These figures are below typical thresholds for healthy performance in the specialty chemicals industry, where return on equity and return on assets are key indicators of operational efficiency and capital utilization. The company's revenue is reported at $0, indicating no current revenue generation. There is no disclosed segment or geographic breakdown of revenue, as the company is not generating revenue at this time. This lack of revenue concentration data suggests the company is in an early or development phase. The company's growth trajectory is not quantifiable due to the absence of historical revenue data and the current zero revenue figure. The outlook for the current fiscal year and the next fiscal year is not provided, but the company's financial position suggests a need for significant capital or revenue generation to sustain operations. The company faces medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. No dilution adjustments have been applied, and the company's equity position is negative, which may limit its ability to raise additional capital through equity issuance. Recent events include the company's ongoing operations in the development of spider silk-based fibers and materials. No specific recent filings or transcripts are provided in the available data, but the company's financial position suggests a focus on research and development rather than commercial operations.